Repurposing FDA-Approved Drugs for Treatment of 2019-nCoV-induced Disease

SARS/CoV-2最近被确定为2019年12月在武汉首次发现的肺炎爆发的原因，中国说。目前的工作重点是对感染者进行遏制和隔离，目前还没有治疗新冠肺炎的注册药物。因此，已经注册用于治疗其他冠状病毒疾病的药物可能会被用于(标签外)，试图挽救新冠肺炎患者的生命。随着预防和治疗SARS-CoV-2感染的疫苗和药物的开发已被世卫组织和各国政府列为优先事项，许多药物研究正在推进。药物再利用被定义为将已知药物应用于新的适应症。这种方法很有吸引力，因为重新调整用途的药物已经通过了毒性试验。因此，我们的目标是筛选临床批准的药物作为单一或成对组合，用于抗病毒和抗炎药的治疗开发，以控制和治疗新冠肺炎病。我们强烈期望产生的数据将确定新的单一或协同药物对，导致详细的临床前评估，并为临床试验或极端情况下的同情使用提供快速进展的动力。

SARS/CoV-2 was recently identified as the cause of the outbreak of pneumonia first detected in Wuhan, China in December 2019. Current efforts are focused on containment and separation of infected individuals, with no registered drugs for the treatment of COVID-19. Hence, drugs that have been registered for the treatment of other coronavirus conditions might be used (off-label) in an attempt to save the lives of COVID-19 patients. As development of vaccines and drugs for prevention and treatment of SARS-CoV-2 infection have been brought to priority status by WHO and governments, numerous drug studies are moving forward. Drug repurposing is defined as the application of known drugs to new indications. This approach is attractive, as repurposed drugs have already passed toxicity trials. Therefore, we aim to screen clinically approved drugs either as single or pair combinations for the therapeutic development of antiviral and anti-inflammatory agents to control and treat COVID-19 disease. We strongly anticipate the data generated will identify novel single or synergistic drug pairs, lead to detailed pre-clinical evaluation and provide the impetus for rapid progress to clinical trials or compassionate use in extreme cases.